Reaction of 6-hydrazinopurine and 2-hydrazinopyrimidine with 2,2,6,6-tetramethylpiperidone-l-oxyl gives 2,2,6,6-tetramethylpiperidone-l-oxyl-(6-purinyl)hydrazone (3b) and 2,2,6,6-tetramethylpiperidone-l-oxyl-(2-pyrimidinyl) hydrazone (4b) respectively. Compound 3b is inactive even at high dose levels against TLX/5 lymphoma and 3b and 4b are both inactive in tests using the L1210 leukaemia system. C onsiderable effort has been expended by Brow n et a l . 1 on the synthesis of p u rin e N-oxides fo r eva lu a tio n in chem otherapy and oncogenesis assays. T reatm ent of 6 -h y d ra zin o p u rin e5 (3 a) or 2-hyd ra z in o p y rim id in e 6 (4 a) with 2,2,6,6-tetramethylp ip e rid o n e-l-o x y l 7 (5 a) gave the desired free ra d i c a ls 8 3 b and 4 b as stable pale yellow and beige solids respectively. A pproaches to nitroxides using th e lith ium derivative 4 c w ere less successful: when th e free rad ic al 5 a was allowed to r e a c t9 w ith the lith iu m derivative 4 c 10, only the hydroxylam ine derivative 5 b was isolated. T re a tm e n t11 o f Jerf-butyl phenyl n itro n e w ith the lithium derivative 4 c follow ed by au to x id atio n of the ensuing anion resulted in a n itro x id e 4 d as evidenced by ESR spectroscopy (a>j = 1 • 4 6 ; an =4^ • 34 mT) although no attem pt was m ade to isolate th is free radical.
respectively. Compound 3b is inactive even at high dose levels against TLX/5 lymphoma and 3b and 4b are both inactive in tests using the L1210 leukaemia system. C onsiderable effort has been expended by Brow n et a l . 1 on the synthesis of p u rin e N-oxides fo r eva lu a tio n in chem otherapy and oncogenesis assays. C, 5 5 .6 1 ; H, 6 .6 7 ; N, 32.43% . IR (K B r) 3 2 00, 2 9 6 5 , 2 9 2 2 , 1622, 13 2 6 cm " 1. U V 2 9 8 (e, 2.7 xlO4), 2 2 4 (1 .7 xlO4). E SR . triplet, a^ = 1.425 m T (in b en z en e ). 
